FGF23: from academic nephrology to personalized patient́s care.

[1]  Aiqing Li,et al.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy. , 2020, Journal of the American Society of Nephrology : JASN.

[2]  K. Tsuchiya,et al.  Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. , 2019, Kidney international.

[3]  M. Wolf,et al.  GFR-Specific versus GFR-Agnostic Cutoffs for Parathyroid Hormone and Fibroblast Growth Factor-23 in Advanced Chronic Kidney Disease , 2019, American Journal of Nephrology.

[4]  R. Weiskirchen,et al.  Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23) , 2018, Scandinavian journal of clinical and laboratory investigation.

[5]  V. Paradis,et al.  Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease , 2018, The Journal of clinical endocrinology and metabolism.

[6]  Yvette N. Lamb.  Burosumab: First Global Approval , 2018, Drugs.

[7]  X. Mariette,et al.  Iron Supplementation–Induced Phosphaturic Osteomalacia: FGF23 is the Culprit , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  P. Chanson,et al.  Evaluation of a New Fully Automated Assay for Plasma Intact FGF23 , 2017, Calcified Tissue International.

[9]  J. Muñoz-Castañeda,et al.  Differential regulation of renal Klotho and FGFR1 in normal and uremic rats , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  K. White,et al.  The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression , 2017, Bone reports.

[11]  H. Jüppner,et al.  Fibroblast growth factor 23: fueling the fire. , 2016, Kidney international.

[12]  M. Cozzolino,et al.  FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde , 2016, Clinical kidney journal.

[13]  K. White,et al.  Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice , 2016, PLoS biology.

[14]  M. Unruh,et al.  FGF23 signaling impairs neutrophil recruitment and host defense during CKD. , 2016, Journal of Clinical Investigation.

[15]  A. Ullrich,et al.  Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. , 2015, Cell metabolism.

[16]  M. Wolf,et al.  Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production , 2015, Kidney international.

[17]  M. Kuro-o.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism , 2013, Nature Reviews Nephrology.

[18]  B. Lanske,et al.  FGF23 regulates renal sodium handling and blood pressure , 2012, EMBO molecular medicine.

[19]  Marc M. Takeno,et al.  Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet , 2012, Kidney international.

[20]  W. Richards,et al.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. , 2012, The Journal of clinical investigation.

[21]  J. Muñoz-Castañeda,et al.  Calcium deficiency reduces circulating levels of FGF23. , 2012, Journal of the American Society of Nephrology : JASN.

[22]  Edward R. Smith,et al.  Biological variability of plasma intact and C-terminal FGF23 measurements. , 2012, The Journal of clinical endocrinology and metabolism.

[23]  Shi-Chung Chang,et al.  Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation , 2012, Kidney international.

[24]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[25]  G. Navis,et al.  Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[26]  A. Ortiz,et al.  Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  M. Sánchez-Niño,et al.  The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. , 2011, Journal of the American Society of Nephrology : JASN.

[28]  M. Wolf,et al.  Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. , 2011, Journal of the American Society of Nephrology : JASN.

[29]  H. Kobori,et al.  Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  M. Razzaque,et al.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation , 2009, Proceedings of the National Academy of Sciences.

[31]  T. A. Fritz,et al.  Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. , 2009, Endocrinology.

[32]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[33]  Sharon M Moe,et al.  Mechanisms of vascular calcification in chronic kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[34]  F. Kronenberg,et al.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. , 2007, Journal of the American Society of Nephrology : JASN.

[35]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[36]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[37]  T. Shigematsu,et al.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. , 2005, Kidney international.

[38]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[39]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[40]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[41]  M. Kuro-o,et al.  Klotho deficiency causes vascular calcification in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.